{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:20:57Z","timestamp":1773469257959,"version":"3.50.1"},"reference-count":64,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["faseb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["FASEB BioAdvances"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Retinopathy of prematurity (ROP) is a severe retinal disease in premature infants characterized by pathological neovascularization, obliteration of retinal vessels and increased vessel tortuosity. Currently, there are no completely satisfactory treatments for ROP. Pigment epithelium\u2010derived factor (PEDF), a potent inhibitor of angiogenesis, appears late in gestation and its deficiency may be linked to development of ROP. This study investigates the preclinical efficacy of PEDF protein alone or in combination with VEGF antagonists for treating ROP. The safety of PEDF protein in the rat eye was assessed using functional in\u00a0vivo measurements and histology. The efficacy of intravitreal injections (IVI) of various treatments was evaluated in a rat oxygen\u2010induced retinopathy (OIR) model using in\u00a0vivo imaging and flatmount analyses. No functional or histological side\u2010effects were found in rat eyes after intravitreal PEDF protein injection. PEDF protein alone or combined with anti\u2010VEGF drugs significantly reduced pathological neovascularization and vessel obliteration, comparable to the effects of anti\u2010VEGF drugs alone. Regarding arterial tortuosity, treatment with a combination of PEDF, and VEGF antagonist was more effective than treatment with anti\u2010VEGF alone. IVI of PEDF protein is safe. PEDF protein alone or combined with VEGF antagonists shows similar efficacy in reducing pathological neovascularization and vessel obliteration as anti\u2010VEGF agents. Furthermore, only treatments involving PEDF protein, alone or with VEGF antagonists, significantly improved the quality of retinal vasculature. Thus, PEDF protein alone or combined with anti\u2010VEGF agents presents a promising alternative to current anti\u2010VEGF treatments for ROP.<\/jats:p>","DOI":"10.1096\/fba.2024-00059","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:15:54Z","timestamp":1721362554000},"page":"311-326","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduction of pathological retinal neovascularization, vessel obliteration, and artery tortuosity by PEDF protein in an oxygen\u2010induced ischemic retinopathy rat model"],"prefix":"10.1096","volume":"6","author":[{"given":"Shiying","family":"Zhao","sequence":"first","affiliation":[{"name":"Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research University Medical Center, Eberhard Karls University of Tuebingen  Tuebingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Tschulakow","sequence":"additional","affiliation":[{"name":"Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research University Medical Center, Eberhard Karls University of Tuebingen  Tuebingen Germany"},{"name":"OcuTox GmbH Preclinical Drug Assessment  Hechingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subha S.","family":"Karthikeyan","sequence":"additional","affiliation":[{"name":"Department of Gene Therapy University Clinic  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research University Medical Center, Eberhard Karls University of Tuebingen  Tuebingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kochanek","sequence":"additional","affiliation":[{"name":"Department of Gene Therapy University Clinic  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Schraermeyer","sequence":"additional","affiliation":[{"name":"Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research University Medical Center, Eberhard Karls University of Tuebingen  Tuebingen Germany"},{"name":"OcuTox GmbH Preclinical Drug Assessment  Hechingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-511X","authenticated-orcid":false,"given":"Sylvie","family":"Julien\u2010Schraermeyer","sequence":"additional","affiliation":[{"name":"Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research University Medical Center, Eberhard Karls University of Tuebingen  Tuebingen Germany"},{"name":"OcuTox GmbH Preclinical Drug Assessment  Hechingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4847.116404"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.150"},{"key":"e_1_2_9_4_1","first-page":"359","article-title":"Oxygen and the retinal blood vessels","volume":"100","author":"Ashton N","year":"1980","journal-title":"Trans Ophthalmol Soc U K (1962)"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.735335"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1951.tb109040.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.18043\/ncm.78.2.124"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208129"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094809"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.81.5.697"},{"key":"e_1_2_9_11_1","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good WV","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)01017-X"},{"key":"e_1_2_9_14_1","article-title":"Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants","volume":"1999","author":"Andersen CC","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1610-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3126\/nepjoph.v12i2.28993"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-022-02195-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4353129"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218"},{"key":"e_1_2_9_21_1","first-page":"585","article-title":"Comparison of different agents and doses of anti\u2010vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta\u2010analysis","volume":"69","author":"Ortiz\u2010Seller A","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2004.05.002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20130463"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108030"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.1.02008"},{"key":"e_1_2_9_26_1","first-page":"821","article-title":"Pigment epithelium\u2010derived factor suppresses ischemia\u2010induced retinal neovascularization and VEGF\u2010induced migration and growth","volume":"43","author":"Duh EJ","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4455"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107798"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202486199"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02066-z"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4199394"},{"key":"e_1_2_9_32_1","first-page":"1133","article-title":"Pigment epithelium\u2010derived factor (PEDF) based therapy induced photoreceptor survival by stabilising the neovessels in a VEGF overexpression CNV rat model","volume":"64","author":"Tschulakow AV","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1242\/bio.048736"},{"key":"e_1_2_9_34_1","article-title":"Whole mount immunofluorescent staining of the neonatal mouse retina to investigate angiogenesis in\u00a0vivo","volume":"9","author":"Tual\u2010Chalot S","year":"2013","journal-title":"J Vis Exp"},{"key":"e_1_2_9_35_1","first-page":"163","article-title":"Oxygen\u2010induced retinopathy model for ischemic retinal diseases in rodents","volume":"16","author":"Vahatupa M","year":"2020","journal-title":"J Vis Exp"},{"issue":"3","key":"e_1_2_9_36_1","first-page":"693","article-title":"Precapillary patterns and perivascular cells in the retinal microvasculature. A scanning electron microscope study","volume":"188","author":"Pannarale L","year":"1996","journal-title":"J Anat"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.01.008"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3511-y"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1171"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01820-3"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.38.7.397"},{"key":"e_1_2_9_42_1","first-page":"576","article-title":"Variable oxygen exposure causes preretinal neovascularization in the newborn rat","volume":"34","author":"Penn JS","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_9_43_1","first-page":"101","article-title":"Oxygen\u2010induced retinopathy in the mouse","volume":"35","author":"Smith LE","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S94447"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0804"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0895-3"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2022.994890"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1188-4"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.005"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2005.05.005"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101018"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1175"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-24320"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.12.020"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i1.92"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11492"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-1780"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-008-9127-8"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192575"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40292-4"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-9046-2"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9081-8"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1033"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.204701"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031"}],"container-title":["FASEB BioAdvances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fba.2024-00059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:25:43Z","timestamp":1760552743000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fba.2024-00059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1096\/fba.2024-00059"],"URL":"https:\/\/doi.org\/10.1096\/fba.2024-00059","archive":["Portico"],"relation":{},"ISSN":["2573-9832","2573-9832"],"issn-type":[{"value":"2573-9832","type":"print"},{"value":"2573-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"2024-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}